Anzeige
Mehr »
Samstag, 04.10.2025 - Börsentäglich über 12.000 News
Innocan Pharma: Neues Medikament für den Massenmarkt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWCH | ISIN: GB00BMC3RJ87 | Ticker-Symbol: RYH0
Frankfurt
03.10.25 | 15:29
0,258 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SAREUM HOLDINGS PLC Chart 1 Jahr
5-Tage-Chart
SAREUM HOLDINGS PLC 5-Tage-Chart

Aktuelle News zur SAREUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.09.Sareum Holdings PLC - Exercise of Warrants-
18.09.Sareum Holdings PLC - Exercise of Warrants-
26.08.Sareum Holdings PLC - Exercise of Warrants-
20.08.Sareum Holdings PLC - Exercise of Warrants-
13.08.Sareum Holdings - New collaboration cements focus on CNS354Sareum has announced a strategic collaboration with Receptor.AI, a 'techbio' company harnessing generative AI to accelerate drug discovery across a range of targets, including TYK2. Sareum had previously...
► Artikel lesen
12.08.Sareum shares climb on partnership with AI-driven drug discovery firm3
12.08.Sareum Holdings PLC - Sareum Collaboration with Receptor.AI1
SAREUM Aktie jetzt für 0€ handeln
09.07.Sareum Holdings PLC - Exercise of Warrants-
04.07.Sareum Holdings PLC - Appointment of Sole Broker1
03.06.Sareum Holdings - A decisive step towards Phase II327Sareum Holdings has reported the initiation of toxicology studies required ahead of the Phase II studies for its lead TYK2/JAK1 asset, SDC-1801. We view this as a key milestone in SDC-1801's development...
► Artikel lesen
29.05.Sareum starts toxicology studies for lead inhibitor-
29.05.Sareum Holdings PLC - Initiation of Toxicology Studies for SDC-1801-
28.04.Sareum Holdings PLC - Update on TYK2/JAK1 and SRA737 Programmes1
24.04.Sareum Holdings PLC - Exercise of Warrants1
10.04.Sareum Holdings - Broader pipeline, bigger milestones284Sareum Holdings' H125 results (to 31 December 2024) summarised a period of operational progress and an improved capital position, with successful fund-raising. Since the completion of the Phase I trial...
► Artikel lesen
14.03.Sareum Holdings - New fund-raise and licence signal active 2025414Sareum Holdings has announced the acquisition of the licence for SRA737, a checkpoint kinase 1 (CHK1) inhibitor, in which the company had previously held a 27.5% economic interest. Following this acquisition...
► Artikel lesen
12.11.24Sareum Holdings - SDC-1801 prepping to enter Phase II370Sareum Holdings' FY24 results summarised an active period for lead asset SDC-1801, a dual TYK2/JAK1 inhibitor, which successfully completed Phase I trials in Australia and is now undergoing preparatory...
► Artikel lesen
11.10.24Sareum Holdings - New funding extends runway to Phase II395Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1